公司资料
Petros Pharmaceuticals 股价、新闻与催化剂
- 股票代码:
- PTPI
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.00 USD (-51.47%)
收盘价
最后更新: 2026年10月1日
—
市值
股价为何变动
截至 2026年10月1日，PTPI 下跌 51.5%，收于 $0.0033。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Rx-to-OTC Technology Developer
Petros Pharmaceuticals is developing technology intended to help prescription medicines transition to nonprescription use. The company has exited its former commercial pharmaceutical and men's-health device businesses.
Software-as-a-Service Platform
The planned platform is intended to help pharmaceutical companies design and operate consumer-facing processes required for prescription-to-over-the-counter switches. Potential functions include education, self-selection, eligibility logic, and commercialization support.
Consumer Decision Interface
Petros is also developing a potential Software as a Medical Device component that would guide consumers through appropriate self-selection or deselection. The interface is intended to reduce subjectivity through clinically established decision logic.
ACNU Regulatory Framework
The strategy is aligned with the FDA's framework for nonprescription drug products with an additional condition for nonprescription use. Under this model, technology can help consumers use a medicine safely when the drug label alone is insufficient.
Discontinued Legacy Operations
Petros no longer commercializes STENDRA and has assigned the assets of its former vacuum-erection-device businesses to a third party. The company therefore operates as an early-stage technology developer rather than a current product marketer.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。